The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...

Up to 2 million people in the U.S. experience rapid-fire heartbeats from time to time, and many end up in the hospital for treatment. But an investigational nasal spray may help folks with paroxysmal ...

Please provide your email address to receive an email when new articles are posted on . A fast-acting nasal spray was safe and effective for patients self-treating for repeated episodes of paroxysmal ...

Etripamil nasal spray (Milestone Pharmaceuticals) continues to show promise as a way for patients to treat their own paroxysmal supraventricular tachycardia (PSVT) without the need for an emergency ...

PSVT involves episodes of a faster-than-normal heart rate, often with symptoms resembling anxiety attacks, and while uncomfortable, it’s typically not life threatening. Diagnosis of PSVT typically ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a rapid-acting nasal spray for the treatment of acute symptomatic paroxysmal supraventricular ...

MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of ...

Credit: Milestone Pharmaceuticals Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil. Cardamyst is expected to be ...

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...

MONTREAL, Nov. 24, 2014 /CNW Telbec/ - Milestone Pharmaceuticals, Inc. today announced data from a Phase 1 clinical trial conducted in Melbourne, Australia of MSP-2017, a novel calcium channel ...

Milestone Pharmaceuticals Inc. received FDA approval for CARDAMYST, a nasal spray for acute PSVT episodes, but faces a challenging commercialization path. The PSVT market is crowded with effective, ...